ArticleTransplantation2009
Human beta-cell precursors mature into functional insulin-producing cells in an immunoisolation device: implications for diabetes cell therapies.
Article in Transplantation, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 112 citations in OpenAlex.
- Allogeneic islet products for type 1 diabetes: Navigating nonclinical and manufacturing regulatory expectations.Stem cell reports · 2026Review
- Voxelated bioprinting of modular double-network bio-ink droplets.Nature communications · 2024Article
- In vitro oxygen imaging of acellular and cell-loaded beta cell replacement devices.Scientific reports · 2023Article
- Hypoxia within subcutaneously implanted macroencapsulation devices limits the viability and functionality of densely loaded islets.Frontiers in transplantation · 2023Article
- Cell delivery systems: Toward the next generation of cell therapies for type 1 diabetes.Journal of cellular and molecular medicine · 2022Review
- Immune-Protective Formulations and Process Strategies for Improved Survival and Function of Transplanted Islets.Frontiers in immunology · 2022Review
- Engineering islets from stem cells for advanced therapies of diabetes.Nature reviews. Drug discovery · 2021Review
- A therapeutic convection-enhanced macroencapsulation device for enhancing β cell viability and insulin secretion.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Hiding in plain sight: an encapsulated approach to cardiac cell therapy.Cardiovascular research · 2021Article
- A 3D culture platform enables development of zinc-binding prodrugs for targeted proliferation of β cells.Science advances · 2020Article
- Engineering Strategies to Improve Islet Transplantation for Type 1 Diabetes Therapy.ACS biomaterials science & engineering · 2020Article
- Review
- Induced Pluripotent Stem Cells: Reprogramming Platforms and Applications in Cell Replacement Therapy.BioResearch open access · 2020Article
- Macroencapsulated Human iPSC-Derived Pancreatic Progenitors Protect against STZ-Induced Hyperglycemia in Mice.Stem cell reports · 2019Article
- Insulin-producing Cells from Adult Human Bone Marrow Mesenchymal Stromal Cells Could Control Chemically Induced Diabetes in Dogs: A Preliminary Study.Cell transplantation · 2018Article
- Combining Induced Pluripotent Stem Cells and Genome Editing Technologies for Clinical Applications.Cell transplantation · 2018Article
- Encapsulation of Human Islets Using a Biomimetic Self-Assembled Nanomatrix Gel for Protection against Cellular Inflammatory Responses.ACS biomaterials science & engineering · 2017Article
- Human islet xenotransplantation in rodents: A literature review of experimental model trends.Clinics (Sao Paulo, Brazil) · 2017Review
- Therapeutic potential of human embryonic stem cells in type 2 diabetes mellitus.World journal of stem cells · 2016Article
- Cell therapies for pancreatic beta-cell replenishment.Italian journal of pediatrics · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
backgroundIslet transplantation is limited by the need for chronic immunosuppression and the paucity of donor tissue. As new sources of human beta-cells are developed (e.g., stem cell-derived tissue), transplanting them in a durable device could obviate the need for immunosuppression, while also protecting the patient from any risk of tumorigenicity. Here, we studied (1) the survival and function of encapsulated human beta-cells and their progenitors and (2) the engraftment of encapsulated murine beta-cells in allo- and autoimmune settings.
methodsHuman islets and human fetal pancreatic islet-like cell clusters were encapsulated in polytetrafluorethylene devices (TheraCyte) and transplanted into immunodeficient mice. Graft survival and function was measured by immunohistochemistry, circulating human C-peptide levels, and blood glucose levels. Bioluminescent imaging was used to monitor encapsulated neonatal murine islets.
resultsEncapsulated human islet-like cell clusters survived, replicated, and acquired a level of glucose responsive insulin secretion sufficient to ameliorate hyperglycemia in diabetic mice. Bioluminescent imaging of encapsulated murine neonatal islets revealed a dynamic process of cell death followed by regrowth, resulting in robust long-term allograft survival. Further, in the non-obese diabetic (NOD) mouse model of type I diabetes, encapsulated primary beta-cells ameliorated diabetes without stimulating a detectable T-cell response.
conclusionsWe demonstrate for the first time that human beta-cells function is compatible with encapsulation in a durable, immunoprotective device. Moreover, our study suggests that encapsulation of beta-cells before terminal differentiation will be a successful approach for new cell-based therapies for diabetes, such as those derived from stem cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.